These suggest that ubenimex combined with pemetrexed in lung adenocarcinoma treatment could be therefore achieved by upregulating SOCS1 expression and then inhibiting the JAK2-STAT3 signaling pathway, further confirming the negative regulatory effect of SOS1 on the JAK2/STAT3 signaling pathway. The gene discussed is SOS1; the disease is lung adenocarcinoma.